Izun nominates Dr Elliot Hahn as Executive Director

May 29, 2012

Dr. Elliot F. Hahn was appointed to the position of executive director of Izun. Dr. Hahn is also the Executive Chairman of Accu-Break Pharmaceuticals, Inc., a privately held company.  He co-founded Andrx Corporation and was Chairman Emeritus and a Director of Andrx until its acquisition by Watson Pharmaceuticals, Inc. in November 2006 for $1.9 billion.

He was President of Andrx from 1993 until 2003, served as Chairman of the Board from 2002-03 and as interim CEO from 2001-02.  From June 1990 until February 1993, Dr. Hahn was Vice President for Scientific Affairs of IVAX, where he was involved in the evaluation and licensing of product opportunities and was responsible for maintaining IVAX’s intellectual property. Prior to that, he was Vice President of Research at the pharmaceutical subsidiary of IVAX. Before joining IVAX, Dr. Hahn was an associate professor at The Rockefeller University, an assistant professor at Albert Einstein College of Medicine, and a member of the Institute for Steroid Research at Montefiore Hospital, all in New York City.  Dr. Hahn received a B.S. with Honors in Chemistry from the City College of New York and a Ph.D. in Organic Chemistry from Cornell University. He has authored or co-authored over sixty peer-reviewed scientific publications.

Dr. Hahn brings extensive knowledge of drug development and the wisdom of many years’ experience in the field. Management is extremely excited that he has agreed to join the Izun Pharmaceuticals board and look forward to his participation in strategic company decisions.